Immunohistochemical evidence of dysregulation of the mammalian target of rapamycin pathway in primary and metastatic pheochromocytomas

Urology

Volumn 80, Issue 3, 2012, Pages 736.e7-736.e12

  Chaux, Alcides ^a,c,d   Brimo, Fadi ^a,c,d   Gonzalez Roibon, Nilda ^a   Shah, Smit ^a   Schultz, Luciana ^a   Rizk, Jean Marc ^c   Argani, Pedram ^a   Hicks, Jessica ^a   Netto, George J ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d Universidad del Norte School of Medicine   (Paraguay)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P27; S6 KINASE;

ADOLESCENT; ADRENAL MEDULLA; ADULT; AGED; ARTICLE; BONE METASTASIS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; METASTASIS; PHEOCHROMOCYTOMA; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SCHOOL CHILD; TISSUE MICROARRAY;

EID: 84865503831     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2012.04.032     Document Type: Article

References (27)

1. V.E. Strong, T. Kennedy, H. Al-Ahmadie Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis Surgery 143 2008 759 768
2. L.D. Thompson Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases Am J Surg Pathol 26 2002 551 566
3. H. Ahlman Malignant pheochromocytoma: state of the field with future projections Ann N Y Acad Sci 1073 2006 449 464
4. G. Eisenhofer, S.R. Bornstein, F.M. Brouwers Malignant pheochromocytoma: current status and initiatives for future progress Endocr Relat Cancer 11 2004 423 436
5. J.T. Adler, G.Y. Meyer-Rochow, H. Chen Pheochromocytoma: current approaches and future directions Oncologist 13 2008 779 793
6. A. Szalat, M. Fraenkel, V. Doviner Malignant pheochromocytoma: predictive factors of malignancy and clinical course in 16 patients at a single tertiary medical center Endocrine 39 2011 160 166
7. R. Adjall, P.F. Plouin, K. Pacak Treatment of malignant pheochromocytoma Horm Metab Res 41 2009 687 696
8. D.J. Gross, E. Schlank, E. Ipp Streptozotocin therapy for malignant pheochromocytoma Arch Intern Med 145 1985 367 368
9. T. Scholz, G. Eisenhofer, K. Pacak Clinical review: current treatment of malignant pheochromocytoma J Clin Endocrinol Metab 92 2007 1217 1225
10. S.E. Bates, C.Y. Shieh, L.A. Mickley Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas J Clin Endocrinol Metab 73 1991 18 29
11. D.J. Gross, G. Munter, M. Bitan The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R Endocr Relat Cancer 13 2006 535 540
12. L. Schultz, R. Albadine, J. Hicks Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy Cancer 116 2010 5517 5526
13. T. Seufferlein, E. Rozengurt Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells Cancer Res 56 1996 3895 3897
14. E. Missiaglia, I. Dalai, S. Barbi Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway J Clin Oncol 28 2010 245 255
15. J.C. Yao, M.H. Shah, T. Ito Everolimus for advanced pancreatic neuroendocrine tumors N Engl J Med 364 2011 514 523
16. J.E. Harthill, M. Pozuelo Rubio, F.C. Milne Regulation of the 14-3-3-binding protein p39 by growth factors and nutrients in rat PC12 pheochromocytoma cells Biochem J 368 2002 565 572
17. Y. Saito, Y. Tanaka, Y. Aita Sunitinib induces apoptosis in pheochromocytoma tumor cells by inhibiting VEGFR2/AKT/mTOR/S6K1 pathways through modulation of Bcl-2 and BAD Am J Physiol Endocrinol Metab 302 2012 E615 E625
18. J.A. Engelman Targeting PI3K signalling in cancer: opportunities, challenges and limitations Nat Rev Cancer 9 2009 550 562
19. M.R. Druce, G.A. Kaltsas, M. Fraenkel Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001) Horm Metab Res 41 2009 697 702
20. H.L. Fedor, A.M. De Marzo Practical methods for tissue microarray construction Methods Mol Med 103 2005 89 101
21. L. Schultz, A. Chaux, R. Albadine Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas Am J Surg Pathol 35 2011 1549 1556
22. Chaux A, Schultz L, Albadine R, et al. Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in papillary cell renal cell carcinomas. Hum Pathol. (In press).
23. J. Favier, P. Igaz, N. Burnichon Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma Endocr Pathol 23 2012 34 42
24. S. Jiang, P.L. Dahia Minireview: the busy road to pheochromocytomas and paragangliomas has a new member, TMEM127 Endocrinology 152 2011 2133 2140
25. Y. Jiao, C. Shi, B.H. Edil DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors Science 331 2011 1199 1203
26. M.R. Clarke, R.J. Weyant, C.G. Watson Prognostic markers in pheochromocytoma Hum Pathol 29 1998 522 526
27. B. Gao, F. Meng, W. Bian Development and validation of pheochromocytoma of the adrenal gland scaled score for predicting malignant pheochromocytomas Urology 68 2006 282 286